Abstract
FK506 (also known as tacrolimus) is a potent immunosuppressive agent that is widely used in the treatment of graft-rejection and autoimmune diseases. FK506 has attracted additional attention owing to its potential role in osteogenic differentiation and bone formation. MicroRNAs (miRNAs) have been demonstrated to serve important roles in the regulation of osteogenic differentiation; however, identification of specific miRNAs and their roles in regulating FK506-induced osteogenic differentiation have been poorly examined. In the present study, osteodifferentiation of rat bone marrow stromal cells (BMSCs) was induced with varying concentrations of FK506 (5–5,000 nM) for 3, 7 and 14 days. Differentially expressed miRNAs were profiled using miRNA array, verified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and subjected to gene ontology (GO) term and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Results from the present study identified a subset of miRNAs that were differentially expressed, of which five upregulated miRNAs (miR-106b-5p, miR-101b-3p, miR-193a-3p, miR-485-3p and miR-142-3p) and four downregulated miRNAs (miR-27a-3p, miR-207, miR-218a-2-3p and let-7a-5p) were confirmed by RT-qPCR. GO and KEGG analysis revealed that the predicted target genes of these miRNAs are involved in multiple biological processes and signaling pathways, including cell differentiation and the mitogen-activated protein kinase (MAPK) signaling pathway. Verification of the miRNA-target genes revealed that Smad5, Jagged 1 and MAPK9 were significantly upregulated, whereas Smad7, BMP and activin membrane-bound inhibitor, and dual-specificity phosphatase 2 were significantly downregulated during FK506-induced osteodifferentiation. The present study may provide an experimental basis for further research on miRNA functions during FK506-induced osteogenic differentiation in rat BMSCs.
Keywords: microRNA, FK506, osteogenic differentiation, bone marrow stromal cells
Introduction
FK506 (also known as tacrolimus) is a potent immunosuppressive agent that is used to prevent graft rejection and to treat autoimmune diseases, both experimentally and clinically (1). Over the past decade, several studies have reported that FK506 treatment may increase bone mass and may be a potential treatment for bone defects (2,3). FK506 exposure has been reported to induce osteogenic differentiation by promoting the expression of osteoblastic transcription factors, including core-binding factor α1 (also termed runt related transcription factor 2, Runx2), osteopontin (OPN) and osteocalcin (OCN) (2,3). A previous in vivo study using bone tissue/hydroxyapatite composite demonstrated increased bone formation and higher osteogenic parameters when cultured with FK506 (4). However, other studies reported that FK506 may result in osteoporosis by increasing the expression levels of osteoclast differentiation factor or by inhibiting osteoblast differentiation by suppressing the activity of calcineurin and the expression of Runx2 (5,6). These results suggested that the function of FK506 during osteogenic differentiation was contradictory and required for further study.
MicroRNAs (miRNAs) are small, 22-nucleotides-long, endogenous noncoding RNAs that bind to target mRNAs at the 3′-untranslated region to mediate translation and reduce protein expression levels (7). They are key negative regulators of diverse biological and pathological processes, such as proliferation, migration, apoptosis and differentiation (7,8). A number of miRNAs have been demonstrated to be involved in the differentiation of osteoblasts from bone marrow stromal cells (BMSCs) by regulating specific gene expression (9). One previous study has indicated that miRNA (miR)-96 may promote osteogenic differentiation by suppressing the expression of heparin-binding epidermal growth factor-like growth factor in mouse BMSCs (10). During the process of osteogenic differentiation of BMSCs, miR-205 was downregulated and inhibition of miR-205 enhanced osteogenic differentiation by regulating the expression of special AT-rich sequence-binding 2 (SATB2) and Runx2 (11). However, identification of specific miRNAs and their regulatory roles in the FK506-induced osteodifferentiation have been poorly investigated.
The aim of the present study was to examine the effects of various concentrations of FK506 (5–5,000 nM) on the osteogenic differentiation of rat BMSCs. Differentially expressed miRNAs were profiled by miRNA array, verified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and subjected to gene ontology (GO) term and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.
Materials and methods
Isolation and culture of rat BMSCs
Primary BMSCs were harvested from 5 male Sprague Dawley rats (age, 4–5 weeks; weight, 80–100 g) using previously described methods (2). The male Sprague-Dawley rats were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). The rats were maintained in a temperature controlled room (22±3°C) with a 12-h light/dark cycle and were allowed free access to drinking water and food. All procedures were approved by The Animal Research Committee of Zhongshan Hospital, Fudan University (Shanghai, China). Briefly, rats were sacrificed by cervical dislocation followed by soaking in 75% ethanol for 10 min. The tibias and femurs from both legs of each rat were dissected and the two ends of each bone were cut under aseptic conditions. The marrow was flushed out with rat Mesenchymal Stem Cell Growth medium (Cyagen Biosciences, Inc., Santa Clara, CA, USA) containing 10% fetal bovine serum, 1% penicillin/streptomycin and 1% glutamine. The cells were centrifuged at 500 × g for 5 min at 4°C, resuspended with Mesenchymal Stem Cell Growth medium, plated in 25 cm2 culture flasks and incubated at 37°C in 5% CO2. The medium was replaced every 3 days and non-adherent cells were removed. The cells reached ~80% confluence at 10–14 days of culture, and were subsequently dissociated using TrypLE Express (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and subcultured to passage 3 for further analysis. The cells were analyzed using an Olympus SZX12 (Olympus Corporation, Tokyo, Japan) inverted microscope equipped with a digital camera and connected to a PC using MagnaFire 2.0 camera software (Optronics, Goleta, CA, USA).
Phenotype analysis
BMSC cell-surface markers were analyzed by flow cytometry. Briefly, cells at passage 3 with 80% confluence were trypsinized using TrypLE Express (Gibco; Thermo Fisher Scientific, Inc.), washed twice with PBS and centrifuged at 500 × g for 5 min at 4°C. Cells were diluted with stain buffer (BD Bioscience, Franklin Lakes, NJ, USA) and the cell number was determined by cell counting assay following the manufacturer's instructions (Precision Instrument Co. Ltd., Shanghai, China). Following counting, a 100 µl cell suspension containing 5×105 cells was added to flow tubes, mixed with rat antibodies, including 1 µl FITC-labeled anti-CD29 (1:100; cat. no. 102205; BioLegend, Inc., San Diego, CA, USA), anti-CD45 (1:100; cat. no. 202205; BioLegend, Inc.) and anti-CD90 (1:100; cat. no. 206105; BioLegend, Inc.) and 2.5 µl phycoerythrin (PE) -labeled anti-CD34 (1:40; cat. no. ab187284; Abcam, Cambridge, UK), and incubated in dark for 40 min at 4°C. Following two washes with PBS, the stained cells were resuspended in 300 µl PBS and immediately analyzed using a BD FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Identification of rat BMSCs was performed in triplicate. The mouse immunoglobulin G1, κ was used as an isotype control (BioLegend, Inc.) and stain buffer was used as blank control. Data were analyzed using FlowJo software version 10 (Tree Star, Inc., Ashland, OR, USA).
Osteogenic differentiation
Cells at passage 3 with 80% confluence were trypsinized using TrypLE Express and seeded into six plates at 1×104 cells/cm2 and incubated with Mesenchymal Stem Cell Growth medium at 37°C for 24 h. Following incubation, the growth medium was replaced with 2 ml osteo-induction medium was prepared as previously described (12) containing 10 mM Na β-glycerophosphate (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), 0.25 mM l-ascorbic acid (MP Biomedicals, LLC, Santa Ana, CA, USA) and 0, 5, 50, 500 or 5,000 nM FK506 (Sigma-Aldrich; Merck KGaA). The osteo-induction medium was replaced every other day; cells were collected at 3, 7 and 14 days for RT-qPCR analysis, and phenotype staining was done at 7 or 14 days. All biochemical assays were carried out at least three times.
Alkaline phosphatase (ALP) and alizarin red S (ARS) staining
ALP staining was performed following 7 days osteogenic stimulation. Briefly, cells were rinsed twice with PBS and fixed with 4% formaldehyde for 30 min at room temperature. The fixed cells were stained with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium solution (Beyotime Institute of Biotechnology, Shanghai, China) for 30 min at room temperature and washed 3 times with PBS. ARS staining was used to assess mineral deposition produced at late-stage bone formation. Briefly, following 14 days osteogenic stimulation, cells were washed twice with PBS, fixed with 4% formaldehyde for 30 min at room temperature, washed twice with PBS and then stained with the Alizarin Red S Solution (Cyagen Biosciences, Inc., Chicago, USA) for 30 min at room temperature. Following ARS staining, the cells were washed 3 times with PBS. Images were captured using an Olympus SZX12 inverted microscope equipped with a digital camera and connected to a PC using MagnaFire 2.0 camera software.
RNA extraction and RT-qPCR analysis
According to the manufacturer's protocol, total RNA was extracted from 1×105 control and FK506-induced BMSCs with TRIzol Reagent (Invitrogen, Carlsbad, USA), purified using the RNeasy Mini Kit (Qiagen, CA, USA) and quantitated by using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). RNA (500 ng) was reverse transcribed into cDNA using the PrimeScript™ RT-PCR kit (Takara Bio, Inc., Otsu, Japan). The cDNA was amplified using the SYBR Premix Ex Taq II kit (Takara Bio, Inc.) with the GeneAmp-PCR system 7500 (Thermo Fisher Scientific, Inc.). Total RNA for miRNA analysis was isolated using a miRCute miRNA Isolation kit (Tiangen Biotech Co., Ltd., Beijing, China) and the expression of mature miRNA was determined by miRCute miRNA PCR Detection kit (Tiangen Biotech Co., Ltd.) with the GeneAmp-PCR system 7500. All primers used for RT-qPCR are listed in the Table I, and each sample was measured in triplicate. Gene expression results of mRNA or miRNA were evaluated by the 2−ΔΔCq method (13) and normalized to GAPDH or U6, respectively.
Table I.
Primer sequences for reverse transcription-quantitative polymerase chain reaction analysis.
| Gene | Primer sequence (5′→3′) |
|---|---|
| Sp7 | F: GAGGCACAAAGAAGCCATACA |
| R: GGGAAAGGGTGGGTAGTCAT | |
| OCN | F: ACAAGTCCCACACAGCAACTC |
| R: CCAGGTCAGAGAGGCAGAAT | |
| Runx2 | F: CACCTCTGACTTCTGCCTCTG |
| R: GATGAAATGCCTGGGAACTG | |
| OPN | F: CTTGGCTTACGGACTGAGG |
| R: GCAACTGGGATGACCTTGAT | |
| Smad7 | F: TCGGAAGTCAAGAGGCTGTG |
| R: CTGGACAGTCTGCAGTTGGTT | |
| MAPK9 | F: AACTCGCTACTATCGGGCTC |
| R: TGGGAACAGGACTTTATGGAGG | |
| Smad5 | F: CCAGTGTTAGTGCCTCGTCA |
| R: GTGGAAGGAATCAGGAAACG | |
| Bambi | F: CATTGCTGGCGGACTGAT |
| R: TCCCTTCTTGGAGTGGTGTC | |
| Dusp2 | F: GGTGGTCCTGTGGAAATCTT |
| R: GAATGCTCTTGTAGCGGAAAA | |
| Jag1 | F: TGCTTGGTGACAGCCTTCTA |
| R: TGGGGTTTTTGATTTGGTTC | |
| GAPDH | F: CAGTGCCAGCCTCGTCTCAT |
| R: AGGGGCCATCCACAGTCTTC |
Bambi, BMP and activin membrane-bound inhibitor; Dusp2, dual-specificity phosphatase 2; F, forward; Jag1, jagged 1; MAPK9, mitogen-activated protein kinase 9; OCN, osteocalcin; OPN, osteopontin; R, reverse; Runx2, runt-related 2.
miRNA microarray analysis
miRNA microarray analysis was performed by KangChen Bio-tech Inc. (Shanghai, China). Briefly, total RNA was extracted from 1×107 control and FK506-induced BMSCs using TRIzol reagent and purified with RNeasy Mini kit (Qiagen, Inc., Valencia, CA, USA), according to manufacturer's protocol. The quality and quantity of RNA were measured by using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA), and RNA integrity was determined using 1.5% gel electrophoresis. miRNAs were labeled with Hy3/Hy5 fluorescence dyes using the miRCURY LNA microRNA Array Power Labeling kit (Exiqon A/S, Vedbaek, Denmark) and hybridized in a Hybridization Chamber II (Ambion; Thermo Fisher Scientific, Inc.) using the miRCURY LNA microarray kit (Exiqon A/S) according to the manufacturer's protocol. Following hybridization, the microarray slides were processed with an Axon GenePix 4000B Microarray Scanner (Axon Instruments; Molecular Devices, LLC, Sunnyvale, CA, USA), and data analysis was performed using GenePix Pro software version 6.0 (Molecular Devices, LLC). The experiment was performed with 3 samples both in control and treatment group, and miRNAs were defined as differentially expressed if changes in expression levels were ≥2-fold than those of the controls.
GO analysis and KEGG pathway annotation based on miRNA expression profile
Target genes of the differentially expressed miRNAs were predicted using miRBase (http://www.mirbase.org), miRanda (http://www.microrna.org), TargetScan (http://www.targetscan.org) and miRDB (http://mirdb.org/miRDB) databases. GO analysis was performed using the Database for Annotation, Visualization and Integrated Discovery (https://david.ncifcrf.gov) to determine the functions of the predicted target genes and to uncover the miRNA-target gene regulatory network based on the predicted biological processes and molecular functions. KEGG pathway analysis (http://www.genome.jp/kegg) was used to determine the potential pathways that the predicted target genes may be a part of. Fisher's exact test and the χ2 test were used to classify the GO category and KEGG pathway, and the false discovery rate (FDR) (14) was calculated to correct the P-value. Thresholds of P<0.05 and FDR<0.05 were used to select significant GO categories. Fisher P-value stands for the enrichment P-value used Fisher's exact test and Fisher-P value<0.05 was used as a threshold to select significant KEGG pathways.
Statistical analysis
Statistical analysis of two groups was determined by unpaired Student's t-test. All data were represented as the mean ± standard error of the mean. P<0.05 was considered to indicate a statistically significant difference.
Results
Growth characteristics and phenotype of BMSCs using flow cytometry
Following 3 days of primary culture, the isolated BMSCs were mostly spindle shaped, single or small colony size and grew at a low density. (Fig. 1A). Primary BMSCs cultured for 12 days replicated rapidly and reached ~80% confluence (Fig. 1B). Cells were expanded by successive subculture and exhibited colony-like growth at passage 3. BMSCs phenotypes were verified by flow cytometric analysis. The subcultured BMSCs at passage 3 were positive for MSCs markers CD29 (99.9%) and CD90 (99.3%), and negative for hematopoietic lineage markers CD34 (0.998%) and CD45 (0.064%) (Fig. 1C).
Figure 1.
Growth characteristics and phenotypic analysis of rat BMSCs. Inverted microscope images (40x) reveal that BMSCs in primary culture were (A) mostly spindle-shaped and single cells at day 3 and (B) reached almost 80% confluence at day 12. Flow cytometric analysis indicated that BMSCs at passage 3 were positive for CD29 and CD90, and negative for CD34 and CD45 (C). BMSCs, bone marrow stromal cells; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
FK506-induced osteogenic differentiation of BMSCs
To detect the effects of FK506 treatment on the osteogenic differentiation of BMSCs, cells were collected at passage 3 and cultured in osteo-induction medium with a concentration of FK506 ranging between 5 and 5,000 nM. ALP and ARS staining were strongest in cells treated with 50 nM FK506 (Fig. 2A). RT-qPCR analysis of BMSCs treated with 50 nM FK506 revealed that the expression of Sp7, Runx2, and OPN were significantly increased following 7 days stimulation and OCN expressed significantly at 7 and 14 days. (P<0.05 vs. negative control; Fig. 2B). These results indicated that FK506 treatment has the potential to stimulate the BMSCs differentiation into osteoblasts at a concentration of 50 nM for 7 days of stimulation, and thus this concentration was used for further miRNA array experiments.
Figure 2.
ALP and ARS staining in BMSCs after FK506-induced osteogenic differentiation. (A) ALP and ARS staining were strongest in rat BMSCs when stimulated with FK506 at the concentration of 50 nM. (B) Expression levels of osteoblastic specific genes were significantly increased at 50 nM FK506 treatment for 7 days. *P<0.05 and **P<0.01 compared with NC. Data are expressed as the mean ± standard error of the mean; n=3 per group. ALP, alkaline phosphatase; ARS, alizarin red S; d, days; NC, negative control; OCN, osteocalcin; OPN, osteopontin; Runx2, runt-related 2.
miRNA expression analysis following FK506-induced osteogenic differentiation
To examine the differential expression of miRNAs that are involved in FK506-induced osteodifferentiation of rat BMSCs, miRCURY LNA microarrays were used to profile miRNA expression 7 days following FK506 (50 nM) induction. Comparison with the control group identified a total of 56 miRNAs, including 17 that were upregulated and 39 that were downregulated (Tables II and III, respectively). RT-qPCR analysis was used to verify the microarray results and demonstrated that five miRNAs were upregulated (miR-106b-5p, miR-101b-3p, miR-193a-3p, miR-485-3p and miR-142-3p) and four were downregulated (miR-27a-3p, miR-207, miR-218a-2-3p and let-7a-5p) compared with untreated control cells (Fig. 3).
Table II.
Upregulated microRNAs in FK506-treated rat bone marrow stromal cells vs. untreated cells.
| microRNA | Fold change |
|---|---|
| rno-miR-101b-3p | 2.14 |
| rno-miR-193a-3p | 2.15 |
| rno-miR-485-3p | 3.03 |
| rno-miR-33-5p | 3.03 |
| rno-miR-324-5p | 3.17 |
| rno-miR-142-3p | 3.18 |
| rno-miR-106b-5p | 2.45 |
| rno-miR-185-3p | 2.67 |
| rno-miR-339-5p | 2.34 |
| rno-miR-1843a-5p | 2.32 |
| rno-miR-1839-3p | 2.22 |
| rno-let-7i-3p | 2.19 |
| rno-miR-3068-5p | 2.19 |
| rno-miR-455-5p | 2.06 |
| rno-miR-296-3p | 2.08 |
| rno-miR-345-3p | 2.42 |
| rno-miR-3084b-5p | 3.18 |
miR, microRNA; rno, Rattus norvegicus.
Table III.
Downregulated microRNAs in FK506-treated rat bone marrow stromal cells vs. untreated cells.
| microRNA | Fold change |
|---|---|
| rno-miR-27a-3p | 2.70 |
| rno-miR-218a-2-3p | 3.70 |
| rno-miR-665 | 5.00 |
| rno-miR-542-5p | 10.0 |
| rno-miR-207 | 2.63 |
| rno-miR-329-3p | 3.45 |
| rno-miR-10a-5p | 3.03 |
| rno-miR-450a-5p | 4.12 |
| no-miR-672-3p | 3.45 |
| rno-miR-878 | 3.03 |
| rno-miR-2985 | 2.56 |
| rno-miR-370-5p | 2.38 |
| rno-miR-488-3p | 3.23 |
| rno-miR-193a-5p | 6.67 |
| rno-miR-29b-3p | 2.17 |
| rno-miR-465-5p | 2.33 |
| rno-miR-3560 | 2.13 |
| rno-miR-3596d | 3.70 |
| rno-miR-1956-5p | 50.0 |
| rno-miR-653-3p | 4.76 |
| rno-miR-203a-3p | 7.14 |
| rno-miR-652-5p | 6.25 |
| rno-miR-200c-5p | 4.17 |
| rno-miR-181b-5p | 2.13 |
| rno-miR-1-3p | 2.04 |
| rno-miR-143-5p | 2.70 |
| rno-miR-664-2-5p | 2.38 |
| rno-let-7a-5p | 2.22 |
| rno-miR-3557-5p | 2.08 |
| rno-miR-331-5p | 3.85 |
| rno-let-7f-5p | 3.57 |
| rno-miR-18a-3p | 12.5 |
| rno-miR-30c-1-3p | 2.33 |
| rno-miR-10a-3p | 25.0 |
| rno-miR-487b-3p | 2.38 |
| rno-miR-497-5p | 11.1 |
| rno-miR-582-5p | 2.56 |
| rno-miR-493-5p | 3.45 |
| rno-miR-194-3p | 5.00 |
miR, microRNA; rno, Rattus norvegicus.
Figure 3.
Reverse transcription-quantitative polymerase chain reaction validation of microRNA expression between untreated and FK506-induced rat bone marrow stromal cells. The five upregulated and four downregulated microRNAs were confirmed to be consistent with the results identified by microarray analysis. *P<0.05 compared with NC. Data are expressed as the mean ± standard error of the mean; n=3 per group. miR, microRNA; NC, negative control.
GO category and KEGG pathway analysis
To investigate the specific roles of the nine identified differentially expressed miRNAs in the regulation of osteodifferentiation in BMSCs, target genes were predicted and subjected to GO term and KEGG pathway analysis. GO analysis demonstrated that the highly enriched GO terms targeted by these dysregulated miRNAs were involved in multiple biological processes such as cell differentiation, cell growth and cell migration (Tables IV and V). KEGG pathway analysis revealed the target genes to be highly enriched in 22 upregulated and 21 downregulated signaling pathways, including mitogen-activated protein kinase (MAPK) signaling pathway, calcium signaling pathway and Toll-like receptor signaling pathway (Fig. 4).
Table IV.
Predicted GO term enrichment of the upregulated microRNAs in FK506-induced osteodifferentiation in rat bone marrow stromal cells.
| GO.ID | Category name | Fold enrichment | P-value | FDR |
|---|---|---|---|---|
| GO:0051234 | Establishment of localization | 1.60 | 1.93×10−10 | 5.02×10−7 |
| GO:0048522 | Positive regulation of cellular process | 1.48 | 3.49×10−7 | 3.13×10−4 |
| GO:0048518 | Positive regulation of biological process | 1.42 | 1.01×10−6 | 7.80×10−4 |
| GO:0009605 | Response to external stimulus | 1.71 | 1.34×10−6 | 8.68×10−4 |
| GO:0006464 | Cellular protein modification process | 1.55 | 1.61×10−6 | 8.68×10−4 |
| GO:0048731 | System development | 1.42 | 2.65×10−6 | 1.30×10−3 |
| GO:2000278 | Regulation of DNA biosynthetic process | 8.45 | 3.52×10−6 | 1.46×10−3 |
| GO:0007275 | Multicellular organismal development | 1.38 | 6.08×10−6 | 2.04×10−3 |
| GO:0006873 | Cellular ion homeostasis | 2.40 | 2.69×10−5 | 5.16×10−3 |
| GO:0048514 | Blood vessel morphogenesis | 2.38 | 3.13×10−5 | 5.81×10−3 |
| GO:0016043 | Cellular component organization | 1.33 | 6.33×10−5 | 9.08×10−3 |
| GO:0051247 | Positive regulation of protein metabolic process | 1.85 | 8.64×10−5 | 1.08×10−2 |
| GO:0006875 | Cellular metal ion homeostasis | 2.36 | 9.88×10−5 | 1.19×10−2 |
| GO:0008283 | Cell proliferation | 1.60 | 1.02×10−4 | 1.19×10−2 |
| GO:0007267 | Cell-cell signaling | 1.86 | 1.26×10−4 | 1.33×10−2 |
| GO:0034220 | Ion transmembrane transport | 1.88 | 1.50×10−4 | 1.39×10−2 |
| GO:0051352 | Negative regulation of ligase activity | 1.34 | 1.60 10−4 | 1.39×10−2 |
| GO:0012501 | Programmed cell death | 1.60 | 1.76×10−4 | 1.48×10−2 |
| GO:0007167 | Enzyme linked receptor protein signaling pathway | 1.95 | 2.04×10−4 | 1.66×10−2 |
| GO:0009653 | Anatomical structure morphogenesis | 1.46 | 2.43×10−4 | 1.74×10−2 |
| GO:1902531 | Regulation of intracellular signal transduction | 1.61 | 3.03×10−4 | 1.98×10−2 |
| GO:0051338 | Regulation of transferase activity | 1.94 | 3.54×10−4 | 2.08×10−2 |
| GO:0065009 | Regulation of molecular function | 1.45 | 3.69×10−4 | 2.09×10−2 |
| GO:0051270 | Regulation of cellular component movement | 1.93 | 4.61×10−4 | 2.32×10−2 |
| GO:0006915 | Apoptotic process | 1.55 | 5.82×10−4 | 2.57×10−2 |
| GO:0030334 | Regulation of cell migration | 1.95 | 9.55×10−4 | 3.71×10−2 |
| GO:0010647 | Positive regulation of cell communication | 1.62 | 1.02×10−3 | 3.86×10−2 |
| GO:0051046 | Regulation of secretion | 1.90 | 1.12×10−3 | 4.21×10−2 |
| GO:0006874 | Cellular calcium ion homeostasis | 2.24 | 1.29×10−3 | 4.66×10−2 |
| GO:0051928 | Positive regulation of calcium ion transport | 3.73 | 1.35×10−3 | 4.76×10−2 |
FDR, false discovery rate; GO, gene ontology.
Table V.
Predicted GO term enrichment of the downregulated microRNAs in FK506-induce osteodifferentiation in rat bone marrow stromal cells.
| GO.ID | Category name | Fold enrichment | P-value | FDR |
|---|---|---|---|---|
| GO:0044710 | Single-organism metabolic process | 1.55 | 4.56×10−10 | 8.19×10−7 |
| GO:0071702 | Organic substance transport | 1.98 | 5.32×10−9 | 5.73×10−6 |
| GO:0010648 | Negative regulation of cell communication | 2.32 | 4.75×10−7 | 1.47×10−4 |
| GO:0042981 | Regulation of apoptotic process | 2.00 | 3.06×10−6 | 5.15×10−4 |
| GO:0044237 | Cellular metabolic process | 1.21 | 2.25×10−5 | 2.02×10−3 |
| GO:0048583 | Regulation of response to stimulus | 1.52 | 3.12×10−5 | 2.58×10−3 |
| GO:0006464 | Cellular protein modification process | 1.53 | 3.37×10−5 | 2.63×10−3 |
| GO:0030182 | Neuron differentiation | 1.92 | 3.82×10−5 | 2.94×10−3 |
| GO:0050767 | Regulation of neurogenesis | 2.31 | 5.02×10−5 | 3.57×10−3 |
| GO:0007399 | Nervous system development | 1.65 | 5.04×10−5 | 3.57×10−3 |
| GO:0050804 | Regulation of synaptic transmission | 3.04 | 5.12×10−5 | 3.58×10−3 |
| GO:0065009 | Regulation of molecular function | 1.59 | 5.81×10−5 | 3.89×10−3 |
| GO:0016049 | Cell growth | 2.62 | 9.00×10−5 | 5.25×10−3 |
| GO:2000026 | Regulation of multicellular organismal development | 1.73 | 9.04×10−5 | 5.25×10−3 |
| GO:0044249 | Cellular biosynthetic process | 1.34 | 9.74×10−5 | 5.35×10−3 |
| GO:0030799 | Regulation of cyclic nucleotide metabolic process | 4.18 | 1.44×10−4 | 7.08×10−3 |
| GO:0006954 | Inflammatory response | 2.38 | 1.69×10−4 | 7.71×10−3 |
| GO:0031100 | Organ regeneration | 4.52 | 1.72×10−4 | 7.71×10−3 |
| GO:0043269 | Regulation of ion transport | 2.25 | 1.97×10−4 | 8.51×10−3 |
| GO:0042127 | Regulation of cell proliferation | 1.72 | 2.86×10−4 | 9.77×10−3 |
| GO:0045595 | Regulation of cell differentiation | 1.68 | 4.15×10−4 | 1.31×10−2 |
| GO:0023014 | Signal transduction by phosphorylation | 2.07 | 4.87×10−4 | 1.47×10−2 |
| GO:0055012 | Ventricular cardiac muscle cell differentiation | 10.00 | 5.82×10−4 | 1.67×10−2 |
| GO:0051592 | Response to calcium ion | 3.77 | 6.68×10−4 | 1.84×10−2 |
| GO:0000165 | MAPK cascade | 1.99 | 1.43×10−3 | 3.16×10−2 |
| GO:0017156 | Calcium ion-dependent exocytosis | 4.78 | 1.56×10−3 | 3.31×10−2 |
| GO:0030099 | Myeloid cell differentiation | 2.33 | 2.16×10−3 | 4.00×10−2 |
| GO:0035051 | Cardiocyte differentiation | 3.35 | 2.78×10−3 | 4.78×10−2 |
| GO:0002520 | Immune system development | 1.76 | 2.81×10−3 | 4.78×10−2 |
| GO:0045622 | Regulation of T-helper cell differentiation | 10.00 | 2.98×10−3 | 4.85×10−2 |
FDR, false discovery rate; GO, gene ontology; MAPK, mitogen-activated protein kinase.
Figure 4.
KEGG pathway analysis for predicted target genes. (A) Pathways that may be upregulated in FK506-induced rat BMSCs. (B) Pathways that may be downregulated in FK506-induced rat BMSCs. The horizontal axis is the enrichment of pathways and the vertical axis is the pathway category. Fisher-P-value<0.05 was used as a threshold to select significant KEGG pathways. LgP is the negative logarithm of the Fisher-P-value. ABC, ATP-binding cassette; BMSCs, bone marrow stromal cells; GABA, γ-aminobutyric acid; MAPK, mitogen-activated protein kinase; TNF, tumor necrosis factor.
Verification of the target genes of differentially expressed miRNAs
Osteodifferentiation is driven by a series of complex events that result in the activation of specific transcription factors. Of the predicted target genes and differentially regulated function analysis, only those closely related to osteoblast differentiation, ossification and signal transduction are listed in Table VI. RT-qPCR demonstrated that MAPK9, Smad5 and jagged 1 (Jag1), which are positive regulators of osteogenesis, were significantly upregulated in FK506-induced rat BMSCs undergoing osteogenic differentiation, compared with the untreated control (Fig. 5); whereas dual-specificity phosphatase 2 (Dusp2), Smad7 and BMP and activin membrane-bound inhibitor (Bambi), which are negative regulators of osteodifferentiation, were demonstrated to be significantly downregulated. The results suggested that FK506 treatment may induce osteogenic differentiation by regulating the expression of specific target genes of these differentially expressed miRNAs.
Table VI.
Predicted target genes and functions of microRNAs associated with FK506-induced osteodifferentiation in rat bone marrow stromal cells.
| microRNA | Target genes | Function |
|---|---|---|
| rno-miR-101b-3p | Smad5 | Osteoblast differentiation, ossification |
| TGFβR1 | Receptor for growth factor, protein metabolism | |
| rno-miR-106b-5p | Bambi | Stem cell differentiation, TGF-β receptor signaling |
| Dusp2 | Tissue development, signal transduction | |
| MAP3K2, MAP3K8 and MAPK9 | MAPK cascade, proliferation and differentiation | |
| Smad7 | Regulator of BMP/TGF-β signaling, osteogenesis | |
| rno-miR-142-3p | TGFβR1 | Receptor for growth factor, protein metabolism |
| rno-miR-27a-3p | MAPK9 | MAPK cascade, proliferation and differentiation |
| Smad5 | Osteoblast differentiation, ossification | |
| CBFβ | Osteoblast differentiation, osteogenesis | |
| rno-miR-218a-2-3p | Wnt5a | Stem cell differentiation and proliferation |
| Jag1 | Mesenchymal cell differentiation, osteogenesis | |
| rno-let-7a-5p | TGFβR1 | Receptor for growth factor, protein metabolism |
| AcvR1C | Receptor for growth and differentiation factor | |
| MAPK6 and MAPK9 | MAPK cascade, proliferation and differentiation |
AcvR1c, activin A receptor type 1C; Bambi, BMP and activin membrane-bound inhibitor; BMP, bone morphogenetic protein; CBFβ, core-binding factor β; Dusp2, dual-specificity phosphatase 2; Jag1, jagged 1; MAPK, mitogen-activated protein kinase; MAP3K, mitogen-activated protein kinase kinase kinase; miR, microRNA; rno, Rattus norvegicus; TGF, transforming growth factor; TGFβR1, TGFβ receptor 1.
Figure 5.
Six osteogenic genes that were predicted to be target genes of the differentially expressed microRNAs were confirmed by reverse transcription-quantitative polymerase chain reaction to be significantly regulated in FK506-induced rat bone marrow stromal cells. *P<0.05 and **P<0.01 compared with NC. Data are expressed as the mean ± standard error of the mean; n=3 per group. Bambi, BMP and activin membrane-bound inhibitor; Dusp2, dual-specificity phosphatase 2; Jag1, jagged 1; MAPK9, mitogen-activated protein kinase 9; NC, negative control.
Discussion
FK506 is a powerful and clinically useful immunosuppressant, which has been widely used as a treatment in organ transplantation, atopic dermatitis and rheumatoid arthritis (15). During the treatment of rheumatoid arthritis, a number of studies demonstrated that FK506 treatment could increase bone formation, inhibit osteoclastic bone resorption and improve clinical symptoms (16,17). In addition, it has been reported that FK506 exposure may promote osteogenic and chondrogenic differentiation (18,19), and a change of immunosuppressive monotherapy from cyclosporin A to FK506 may be able to reverse bone loss (20), indicating that FK506 may be a potential treatment for bone defects.
However, other studies demonstrated that FK506 treatment may result in osteoporosis, prevent osteoblast differentiation and/or cause significant bone loss (5,6,21). These conflicting results may be due to different drug concentrations administered or induction time, which is crucial in the process of bone metabolism. Low-dose and short-term application of FK506 may be able to promote the early stage of osteogenesis. By contrast, long-term administration of FK506 led to accelerated bone formation and bone resorption (22). The present study demonstrated that FK506 treatment in rat BMSCs had the most significant osteogenic potential when administered at a dose of 50 nM for 7 days; whereas high concentrations of FK506 or longer periods of stimulation reduced the osteogenic potential, suggesting that the possible side effects of drug cytotoxicity may inhibit the osteoinduction of BMSCs.
miRNAs serve a key role in regulating osteodifferentiation (9). The present study identified and verified five upregulated and four downregulated miRNAs that were differentially expressed in FK506-induced rat BMSCs undergoing osteogenic differentiation, some of which have been reported as positive and/or negative regulators of osteogenesis. For example, miR-27a, an early negative regulator of osteogenesis, was revealed to delay osteoblast differentiation by suppressing SATB2 expression (23). By contrast, a different study reported that miR-27a may be able to promote osteoblast differentiation by repressing the expression of secreted frizzled-related protein at the transcriptional level (24). A previous study revealed that miR-193a was downregulated during osteogenic differentiation of human adipose-derived stem cells and the osteoporotic fractures; however, the mechanism has not been elucidated (25). In addition, miR-218 was reported to be upregulated during osteodifferentiation and its overexpression could significantly increase human adipose tissue-derived stem cells osteogenic differentiation (26). However, results from the present study are not fully in line with the results of previous studies, which may be explained by the variability of mesenchymal stem cells from different tissues and culture microenvironments.
To further investigate the molecular mechanisms of FK506-induced osteogenic differentiation in rat BMSCs, functional analysis were performed. Predicted miRNA target genes, such as MAPK9 and Dusp2, were verified by RT-qPCR. Highly enriched KEGG pathway analysis indicated that MAPK9 and Dusp2 may serve a role through the MAPK signaling pathway, which is involved in a number of cellular functions, such as differentiation, proliferation and cell death (27). Of these, the physiological functions of MAPK9 [(also known as c-Jun N-terminal kinase 2 (JNK2)] in osteodifferentiation and bone formation have been investigated previously (28). MAPK9 activity is essential for the expression of activating transcription factor 4, and its overexpression may enhance mineral deposition that is essential in the late stages osteogenic differentiation (29). Activation of JNKs is also essential for bone morphogenetic protein (BMP) 9-induced osteodifferentiation of mesenchymal stem cells (30). The expression of Dusp2, an inhibitor of osteoblast differentiation, was revealed to be downregulated during osteogenic differentiation (31,32). The DUSP subfamily (DUSP1, DUSP2, DUSP4 and DUSP5) of nucleus-inducible MAPK phosphatases are rapidly induced by growth factors or stress signals, such as mitogens, oxidative stress, heat shock and hypoxia and localize exclusively to the nucleus (32,33). In the present study, MAPK9 expression was revealed to be significantly upregulated in rat BMSCs stimulated with 50 nM FK506 for 7 days, whereas the expression of Dusp2 was downregulated. These data suggested that MAPK9 and Dusp2 are important regulatory components in the process of FK506-induced osteogenesis in rat BMSCs.
Verification of the predicted target genes also demonstrated that Smad5 expression was upregulated, and the expression levels of Smad7 and Bambi were downregulated. Smad5, Smad7 and Bambi belong to the transforming growth factor (TGF) -β/BMP superfamily, which are involved in numerous cellular processes and bone formation (34). Previous studies have indicated that FK506 may be able to induce osteogenic and chondrogenic differentiation by regulating Smads (18,19), the downstream effectors of TGF-β/Smad signaling pathway. Smad5 is a positive regulator in BMP/Smad signaling, and was previously demonstrated to be highly expressed in genistein-induced osteogenic differentiation of human BMSCs (35). Smad5 protein degradation in the Smurf1-overexpression C2C12 mouse myoblast cells was demonstrated to cause the inability to undergo BMP-induced osteoblast differentiation and Smad1/5-knockout mice exhibited severe chondrodysplasia (36,37). Smad7 and Bambi act as negative regulators of osteogenic differentiation: Smad7 was reported to inhibit proliferation, differentiation and mineralization of mouse osteoblastic cells (38); and Bambi, a target gene of miR-20a, was demonstrated to inhibit the osteogenesis of human BMSCs (39). In the present study, although the target genes of differentially expressed miRNAs were not highly enriched in the TGF-β/Smad signaling pathway, it may be concluded that these differentially expressed miRNAs may promote FK506-induced osteogenic differentiation by regulating the expression of their target genes, such as Smad5, Smad7 and Bambi.
In conclusion, the results of the present study demonstrated that FK506 treatment was able to significantly promote osteogenic differentiation of rat BMSCs at the concentration of 50 nM. Following 7 day stimulation, several miRNAs were identified as differentially expressed and may regulate osteodifferentiation by targeting genes that are involved in bone formation. These preliminary results may provide an experimental basis for further research on the functions of miRNAs in FK506-induced osteogenic differentiation.
Acknowledgements
The present study was supported by a grant from the Major Scientific and Technological Research Projects of The Science and Technology Commission of Shanghai Municipality (grant no. 14JC1490600) and a grant from The Natural Science Foundation of Shanghai (grant no. 15ZR1406200).
References
- 1.Tang L, Ebara S, Kawasaki S, Wakabayashi S, Nikaido T, Takaoka K. FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol Int. 2002;26:75–84. doi: 10.1006/cbir.2001.0812. [DOI] [PubMed] [Google Scholar]
- 2.Byun YK, Kim KH, Kim SH, Kim YS, Koo KT, Kim TI, Seol YJ, Ku Y, Rhyu IC, Lee YM. Effects of immunosuppressants, FK506 and cyclosporin A, on the osteogenic differentiation of rat mesenchymal stem cells. J Periodontal Implant Sci. 2012;42:73–80. doi: 10.5051/jpis.2012.42.3.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Iejima D, Lee MH, Kojima H, Yoshikawa T, Wang PC, Uemura T. Cbfa1 expression is enhanced by the immunosuppressant FK506 in the osteoblastic cell line: UMR106. Mater Sci Eng: C. 2004;24:845–850. doi: 10.1016/j.msec.2004.08.024. [DOI] [Google Scholar]
- 4.Yoshikawa T, Nakajima H, Yamada E, Akahane M, Dohi Y, Ohgushi H, Tamai S, Ichijima K. In vivo osteogenic capability of cultured allogeneic bone in porous hydroxyapatite: Immunosuppressive and osteogenic potential of FK506 in vivo. J Bone Miner Res. 2000;15:1147–1157. doi: 10.1359/jbmr.2000.15.6.1147. [DOI] [PubMed] [Google Scholar]
- 5.Fukunaga J, Yamaai T, Yamachika E, Ishiwari Y, Tsujigiwa H, Sawaki K, Lee YJ, Ueno T, Kirino S, Mizukawa N, et al. Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. Bone. 2004;34:425–431. doi: 10.1016/j.bone.2003.05.003. [DOI] [PubMed] [Google Scholar]
- 6.Sun L, Blair HC, Peng Y, Zaidi N, Adebanjo OA, Wu XB, Wu XY, Iqbal J, Epstein S, Abe E, et al. Calcineurin regulates bone formation by the osteoblast. Proc Natl Acad Sci USA. 2005;102:17130–17135. doi: 10.1073/pnas.0508480102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Xu JF, Yang Gh, Pan XH, Zhang SJ, Zhao C, Qiu BS, Gu HF, Hong JF, Cao L, Chen Y, et al. Altered microRNA expression profile in exosomes during osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. PLoS One. 2014;9:e114627. doi: 10.1371/journal.pone.0114627. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Martin EC, Qureshi AT, Dasa V, Freitas MA, Gimble JM, Davis TA. MicroRNA regulation of stem cell differentiation and diseases of the bone and adipose tissue: Perspectives on miRNA biogenesis and cellular transcriptome. Biochimie. 2016;124:98–111. doi: 10.1016/j.biochi.2015.02.012. [DOI] [PubMed] [Google Scholar]
- 9.Fang S, Deng Y, Gu P, Fan X. MicroRNAs regulate bone development and regeneration. Int J Mol Sci. 2015;16:8227–8253. doi: 10.3390/ijms16048227. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Yang M, Pan Y, Zhou Y. miR-96 promotes osteogenic differentiation by suppressing HBEGF-EGFR signaling in osteoblastic cells. FEBS Lett. 2014;588:4761–4768. doi: 10.1016/j.febslet.2014.11.008. [DOI] [PubMed] [Google Scholar]
- 11.Hu N, Feng C, Jiang Y, Miao Q, Liu H. Regulative effect of Mir-205 on osteogenic differentiation of bone mesenchymal stem cells (BMSCs): Possible role of SATB2/Runx2 and ERK/MAPK pathway. Int J Mol Sci. 2015;16:10491–10506. doi: 10.3390/ijms160510491. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Dai W, Dong J, Fang T, Uemura T. Stimulation of osteogenic activity in mesenchymal stem cells by FK506. J Biomed Mater Res A. 2008;86:235–243. doi: 10.1002/jbm.a.31685. [DOI] [PubMed] [Google Scholar]
- 13.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
- 14.Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and powerful Approach to multiple testing. J R Stat Soc B. 1995;57:289–300. [Google Scholar]
- 15.Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem. 2000;7:731–748. doi: 10.2174/0929867003374723. [DOI] [PubMed] [Google Scholar]
- 16.Kang KY, Ju JH, Song YW, Yoo DH, Kim HY, Park SH. Tacrolimus treatment increases bone formation in patients with rheumatoid arthritis. Rheumatol Int. 2013;33:2159–2163. doi: 10.1007/s00296-012-2370-z. [DOI] [PubMed] [Google Scholar]
- 17.Yago T, Nanke Y, Kawamoto M, Yamanaka H, Kotake S. Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation. Cytokine. 2012;59:252–257. doi: 10.1016/j.cyto.2012.04.012. [DOI] [PubMed] [Google Scholar]
- 18.Kugimiya F, Yano F, Ohba S, Igawa K, Nakamura K, Kawaguchi H, Chung UI. Mechanism of osteogenic induction by FK506 via BMP/Smad pathways. Biochem Biophys Res Commun. 2005;338:872–879. doi: 10.1016/j.bbrc.2005.10.024. [DOI] [PubMed] [Google Scholar]
- 19.Tateishi K, Higuchi C, Ando W, Nakata K, Hashimoto J, Hart DA, Yoshikawa H, Nakamura N. The immunosuppressant FK506 promotes development of the chondrogenic phenotype in human synovial stromal cells via modulation of the Smad signaling pathway. Osteoarthritis Cartilage. 2007;15:709–718. doi: 10.1016/j.joca.2007.01.006. [DOI] [PubMed] [Google Scholar]
- 20.Spolidorio LC, Nassar PO, Nassar CA, Spolidorio DM, Muscará MN. Conversion of immunosuppressive monotherapy from cyclosporin a to tacrolimus reverses bone loss in rats. Calcif Tissue Int. 2007;81:114–123. doi: 10.1007/s00223-007-9040-2. [DOI] [PubMed] [Google Scholar]
- 21.Luo L, Shi Y, Bai Y, Zou Y, Cai B, Tao Y, Lin T, Wang L. Impact of tacrolimus on bone metabolism after kidney transplantation. Int Immunopharmacol. 2012;13:69–72. doi: 10.1016/j.intimp.2012.03.019. [DOI] [PubMed] [Google Scholar]
- 22.Kaihara S, Bessho K, Okubo Y, Sonobe J, Kusumoto K, Ogawa Y, Iizuka T. Effect of FK506 on osteoinduction by recombinant human bone morphogenetic protein-2. Life Sci. 2002;72:247–256. doi: 10.1016/S0024-3205(02)02244-0. [DOI] [PubMed] [Google Scholar]
- 23.Hassan MQ, Gordon JAR, Beloti MM, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian JB. A network connecting Runx2, SATB2 and the miR-23a- 27a-24-2 cluster regulates the osteoblast differentiation program. Proc Natl Acad Sci USA. 2010;107:19879–19884. doi: 10.1073/pnas.1007698107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Guo D, Li Q, Lv Q, Wei Q, Cao S, Gu J. MiR-27a targets sFRP1 in hFOB cells to regulate proliferation, apoptosis and differentiation. PLoS One. 2014;9:e91354. doi: 10.1371/journal.pone.0091354. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Zhang Zj Zhang H, Kang Y, Sheng PY, Ma YC, Yang ZB, Zhang ZQ, Fu M, He AS, Liao WM. miRNA expression profile during osteogenic differentiation of human adipose-derived stem cells. J Cell Biochem. 2012;113:888–898. doi: 10.1002/jcb.23418. [DOI] [PubMed] [Google Scholar]
- 26.Zhang WB, Zhong WJ, Wang L. A signal-amplification circuit between miR-218 and Wnt/β-catenin signal promotes human adipose tissue-derived stem cells osteogenic differentiation. Bone. 2014;58:59–66. doi: 10.1016/j.bone.2013.09.015. [DOI] [PubMed] [Google Scholar]
- 27.Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9:726–735. [PubMed] [Google Scholar]
- 28.Wang P, Xiong Y, Ma C, Shi T, Ma D. Molecular cloning and characterization of novel human JNK2 (MAPK9) transcript variants that show different stimulation activities on AP-1. BMB Rep. 2010;43:738–743. doi: 10.5483/BMBRep.2010.43.11.738. [DOI] [PubMed] [Google Scholar]
- 29.Matsuguchi T, Chiba N, Bandow K, Kakimoto K, Masuda A, Ohnishi T. JNK activity is essential for Atf4 expression and late-stage osteoblast differentiation. J Bone Miner Res. 2009;24:398–410. doi: 10.1359/jbmr.081107. [DOI] [PubMed] [Google Scholar]
- 30.Zhao YF, Xu J, Wang WJ, Wang J, He JW, Li L, Dong Q, Xiao Y, Duan XL, Yang X, et al. Activation of JNKs is essential for BMP9-induced osteogenic differentiation of mesenchymal stem cells. BMB Rep. 2013;46:422–427. doi: 10.5483/BMBRep.2013.46.8.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem. 2009;284:15676–15684. doi: 10.1074/jbc.M809787200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Caunt CJ, Rivers CA, Conway-Campbell BL, Norman MR, McArdle CA. Epidermal growth factor receptor and protein kinase C signaling to ERK2: Spatiotemporal regulation of ERK2 by dual specificity phosphatases. J Biol Chem. 2008;283:6241–6252. doi: 10.1074/jbc.M706624200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Jeffrey KL, Camps M, Rommel C, Mackay CR. Targeting dual-specificity phosphatases: Manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov. 2007;6:391–403. doi: 10.1038/nrd2289. [DOI] [PubMed] [Google Scholar]
- 34.Chen G, Deng C, Li YP. TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012;8:272–288. doi: 10.7150/ijbs.2929. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Dai J, Li Y, Zhou H, Chen J, Chen M, Xiao Z. Genistein promotion of osteogenic differentiation through BMP2/SMAD5/RUNX2 signaling. Int J Biol Sci. 2013;9:1089–1098. doi: 10.7150/ijbs.7367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Ying SX, Hussain ZJ, Zhang YE. Smurf1 facilitates myogenic differentiation and antagonizes the bone morphogenetic protein-2-induced osteoblast conversion by targeting Smad5 for degradation. J Biol Chem. 2003;278:39029–39036. doi: 10.1074/jbc.M301193200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Retting KN, Song B, Yoon BS, Lyons KM. BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation. Development. 2009;136:1093–1104. doi: 10.1242/dev.029926. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Yano M, Inoue Y, Tobimatsu T, Hendy G, Canaff L, Sugimoto T, Seino S, Kaji H. Smad7 inhibits differentiation and mineralization of mouse osteoblastic cells. Endocr J. 2012;59:653–662. doi: 10.1507/endocrj.EJ12-0022. [DOI] [PubMed] [Google Scholar]
- 39.Zhang JF, Fu WM, He ML, Xie WD, Lv Q, Wan G, Li G, Wang H, Lu G, Hu X, et al. MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol. 2011;8:829–838. doi: 10.4161/rna.8.5.16043. [DOI] [PubMed] [Google Scholar]